ClinicalTrials.gg
CompletedNCT02198794RIM-TDUpdated Apr 1, 2022Results posted

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

A Phase 3 interventional study of SD-809 and Placebo in Tardive Dyskinesia, sponsored by Auspex Pharmaceuticals, Inc.. Completed at 82 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-01.

Sponsored by Auspex Pharmaceuticals, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.

Enrollment
Largest of 27
343 · median 89
Started
2014
with 4 others
Phase 3
6 of 31
none open now
Registered
12th of 31
by date
Lead sponsor
3 of 31
Auspex Pharmaceuticals, Inc.

Among the 31 studies in Tardive Dyskinesia with a site in United States, this one has the largest enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2014, is one of 6 in phase 3, and was the 12th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Tardive Dyskinesia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.

Read the detailed description

Participants who complete study SD-809-C-18 (NCT02195700), SD-809-C-23 (NCT02291861), or any other SD-809 study will be enrolled in this study. This study include a screening period (Part A), a titration period (Part A), a long-term treatment period (Part A), a double-blind, randomized withdrawal period (Part B), treatment after completion of the randomized withdrawal period (Part B), and a post-treatment safety follow-up period (Part A and Part B). EU participants who complete Part B will be invited to participate in Part C.

03

Conditions studied

  • Tardive Dyskinesia

Keywords

  • Dyskinesias
  • Movement Disorders
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Neurologic Manifestations
  • Signs and Symptoms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of using a dopamine receptor antagonist for at least 3 months
  • Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening
  • Participant has successfully completed a controlled study of SD-809 for treatment of moderate to severe tardive dyskinesia
  • Participants with underlying psychiatric diagnosis are stable and have no change in psychoactive medications
  • Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months
  • History of being compliant with prescribed medications
  • Able to swallow study drug whole
  • Be in good general health and is expected to attend all study visits and complete study assessments
  • Female participants must not be pregnant and agree to an acceptable method of

Exclusion criteria

Exclusion Criteria:

  • Currently receiving medication for the treatment of tardive dyskinesia
  • Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias
  • Have a serious untreated or undertreated psychiatric illness
  • Have recent history or presence of violent behavior
  • Have unstable or serious medical illness
  • Have evidence of hepatic impairment
  • Have evidence of renal impairment
  • Have known allergy to any component of SD-809 or tetrabenazine
  • Has participated in an drug or device trial (other than Study C-18, Study C-23, or any other eligible TEV-50717 parent study) and received study drug within 30 days
  • Have acknowledged use of illicit drugs
  • Have a history of alcohol or substance abuse in the previous 12 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Part A: SD-809

    Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.

    Drug: SD-809

  • Placebo comparator
    Part B: Placebo

    Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.

    Drug: SD-809 · Drug: Placebo

  • Active comparator
    Part B: SD-809

    Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.

    Drug: SD-809

  • Experimental
    Part C: SD-809

    EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.

    Drug: SD-809

Interventions

  • DrugSD-809

    SD-809 will be administered per dose and schedule specified in the arm.

    Also known as: Deutetrabenazine; TEV-50717

  • DrugPlacebo

    Placebo matching to SD-809 will be administered per schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal

    AEs were analyzed as one group combined for parts A and B per planned analysis. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE=prevents normal daily activities. Drug-related TEAEs: TEAEs with possible, probable, or definite relationship to study drug. Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A treatment-emergent AE was defined as an AE that began after the first administration of study medication or existing AEs that worsened after the first dose of study medication. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days)

  2. Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating

    The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

    Time frame: Day 1 of Part B, Day 7 of Part B

Secondary outcomes

  1. Part A: Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating

    The AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

    Time frame: Baseline, Week 145

  2. Part A: Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating

    The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

    Time frame: Baseline, Week 158

  3. Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating

    The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

    Time frame: Baseline, Week 145

  4. Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating

    The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

    Time frame: Baseline, Week 158

  5. Part A: Percentage of Participants Who Had a 50% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating

    The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

    Time frame: Baseline to Week 145

  6. Part A: Percentage of Participants Who Had a 70% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating

    The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

    Time frame: Baseline to Week 145

  7. Part A: Change From Baseline in AIMS Items 8, 9, and 10 Score at Week 145, as Assessed by the Site Rating

    The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. Items 8 to 10 deal with global severity as judged by the examiner, and the participant's awareness of the movements and the distress associated with them. Item 8 (used as an overall severity index indicating severity of abnormal movements) was rated on a 5-point anchored scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Items 9 and 10 (provide additional information with regard to participant's incapacitation due to abnormal movements and participant's awareness of abnormal movements) were rated on a 5-point anchored scale ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Higher scores indicated more severe disease.

    Time frame: Baseline, Week 145

  8. Part A: Percentage of Participants Who Were a Treatment Success, Based on the Clinical Global Impression of Change (CGIC)

    A treatment success was defined as much or very much improved on the CGIC from baseline of this study. The CGIC is a single-item questionnaire that asks the investigator to assess a participant's TD symptoms at specific visits/weeks after initiating therapy. The CGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.

    Time frame: Baseline up to Week 145

  9. Part A: Percentage of Participants Who Were a Treatment Success, Based on the Patient Global Impression of Change (PGIC)

    A treatment success was defined as much or very much improved on the PGIC from baseline of this study. The PGIC is single-item questionnaire that asks the participant to assess their TD symptoms at specific visits/weeks after initiating therapy. The PGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.

    Time frame: Baseline up to Week 145

  10. Part A: Change From Baseline in Modified CDQ-24 Score at Week 158

    The CDQ-24 is a disease-specific quality of life questionnaire developed for use in participants with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ-24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains were evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by participants on a scale of 0 = never or no impairment to 4 = always or very severe impairment. Total score ranged from 0 - 96, with higher score indicative of severe impairment.

    Time frame: Baseline, Week 158

07

Results

Posted Mar 1, 2021

Participant flow

343 participants who completed previous SD-809 studies, including study SD-809-C-18 (NCT02195700) or SD-809-C-23 (NCT02291861) were enrolled and 337 participants were eligible for analysis. 6 participants were not evaluable and were excluded from the analysis due to site data integrity issues as reported to the United States Food and Drug Administration (US FDA).

Part A: Open-Label (158 Weeks)
Participant flow — Part A: Open-Label (158 Weeks)
MilestoneSD-809Part B: PlaceboPart B: SD-809Part C: SD-809
Started337000
Received at least 1 dose of study drug337000
Intent-to-treat (itt) population337000
Participants who participated in part a but not in part b195000
Participants who agreed to continue in part b142000
Completed32000
Not completed305000
Withdrew: Withdrawal by subject79000
Withdrew: Adverse event33000
Withdrew: Lost to follow-up24000
Withdrew: Lack of efficacy9000
Withdrew: Death8000
Withdrew: Noncompliance with study drug3000
Withdrew: Other than specified5000
Withdrew: Study terminated1000
Withdrew: Protocol deviation1000
Withdrew: Agreed to continue in part b142000
Part B: Randomized (13 Weeks)
Participant flow — Part B: Randomized (13 Weeks)
MilestoneSD-809Part B: PlaceboPart B: SD-809Part C: SD-809
Started071710
Randomized withdrawal mitt population063650
Completed066680
Not completed0530
Withdrew: Withdrawal by subject0310
Withdrew: Lost to follow-up0220
Part C: Safety Assessment (52 Weeks)
Participant flow — Part C: Safety Assessment (52 Weeks)
MilestoneSD-809Part B: PlaceboPart B: SD-809Part C: SD-809
Started00080
Completed00073
Not completed0007
Withdrew: Withdrawal by subject0003
Withdrew: Adverse event0002
Withdrew: Death0002

Outcome measures

PrimaryPart A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal

AEs were analyzed as one group combined for parts A and B per planned analysis. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE=prevents normal daily activities. Drug-related TEAEs: TEAEs with possible, probable, or definite relationship to study drug. Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A treatment-emergent AE was defined as an AE that began after the first administration of study medication or existing AEs that worsened after the first dose of study medication. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days)
Reported as:
Count of participants · Participants
Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal
ParticipantsSD-809Part C: SD-809
Any TEAEs26923
Serious TEAEs685
Severe TEAEs573
Drug-Related TEAEs1543
TEAEs Leading to Withdrawal From Study423
PrimaryPart B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating

The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

Time frame:
Day 1 of Part B, Day 7 of Part B
Reported as:
Mean · units on a scale
Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating
units on a scalePart B: PlaceboPart B: SD-809
Pre-withdrawal5.7 ± 0.555.0 ± 0.49
Change at Post-withdrawal0.6 ± 0.280 ± 0.29
Statistical analysis
  • Part B: Placebo vs Part B: SD-809 · ANCOVA · p = 0.121 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -0.6 · 95% CI -1.42 to 0.17
SecondaryPart A: Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating

The AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

Time frame:
Baseline, Week 145
Reported as:
Mean · units on a scale
Part A: Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating
units on a scalePart A: SD-809
Part A: Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating-6.6 ± 0.37
SecondaryPart A: Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating

The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

Time frame:
Baseline, Week 158
Reported as:
Mean · units on a scale
Part A: Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating
units on a scalePart A: SD-809
Part A: Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating-6.3 ± 0.85
SecondaryPart A: Percent Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating

The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

Time frame:
Baseline, Week 145
Reported as:
Mean · percent change
Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating
percent changePart A: SD-809
Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating-57.0 ± 2.43
SecondaryPart A: Percent Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating

The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

Time frame:
Baseline, Week 158
Reported as:
Mean · percent change
Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating
percent changePart A: SD-809
Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating-54.9 ± 6.76
SecondaryPart A: Percentage of Participants Who Had a 50% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating

The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

Time frame:
Baseline to Week 145
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Who Had a 50% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating
percentage of participantsPart A: SD-809
Part A: Percentage of Participants Who Had a 50% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating67
SecondaryPart A: Percentage of Participants Who Had a 70% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating

The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.

Time frame:
Baseline to Week 145
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Who Had a 70% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating
percentage of participantsPart A: SD-809
Part A: Percentage of Participants Who Had a 70% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating42
SecondaryPart A: Change From Baseline in AIMS Items 8, 9, and 10 Score at Week 145, as Assessed by the Site Rating

The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. Items 8 to 10 deal with global severity as judged by the examiner, and the participant's awareness of the movements and the distress associated with them. Item 8 (used as an overall severity index indicating severity of abnormal movements) was rated on a 5-point anchored scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Items 9 and 10 (provide additional information with regard to participant's incapacitation due to abnormal movements and participant's awareness of abnormal movements) were rated on a 5-point anchored scale ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Higher scores indicated more severe disease.

Time frame:
Baseline, Week 145
Reported as:
Mean · units on a scale
Part A: Change From Baseline in AIMS Items 8, 9, and 10 Score at Week 145, as Assessed by the Site Rating
units on a scalePart A: SD-809
Severity of abnormal movements-1.3 ± 0.07
Incapacitation due to abnormal movements-1.3 ± 0.08
Participant's awareness of abnormal movements-1.3 ± 0.09
SecondaryPart A: Percentage of Participants Who Were a Treatment Success, Based on the Clinical Global Impression of Change (CGIC)

A treatment success was defined as much or very much improved on the CGIC from baseline of this study. The CGIC is a single-item questionnaire that asks the investigator to assess a participant's TD symptoms at specific visits/weeks after initiating therapy. The CGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.

Time frame:
Baseline up to Week 145
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Who Were a Treatment Success, Based on the Clinical Global Impression of Change (CGIC)
percentage of participantsPart A: SD-809
Part A: Percentage of Participants Who Were a Treatment Success, Based on the Clinical Global Impression of Change (CGIC)73
SecondaryPart A: Percentage of Participants Who Were a Treatment Success, Based on the Patient Global Impression of Change (PGIC)

A treatment success was defined as much or very much improved on the PGIC from baseline of this study. The PGIC is single-item questionnaire that asks the participant to assess their TD symptoms at specific visits/weeks after initiating therapy. The PGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.

Time frame:
Baseline up to Week 145
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Who Were a Treatment Success, Based on the Patient Global Impression of Change (PGIC)
percentage of participantsPart A: SD-809
Part A: Percentage of Participants Who Were a Treatment Success, Based on the Patient Global Impression of Change (PGIC)63
SecondaryPart A: Change From Baseline in Modified CDQ-24 Score at Week 158

The CDQ-24 is a disease-specific quality of life questionnaire developed for use in participants with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ-24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains were evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by participants on a scale of 0 = never or no impairment to 4 = always or very severe impairment. Total score ranged from 0 - 96, with higher score indicative of severe impairment.

Time frame:
Baseline, Week 158
Reported as:
Mean · units on a scale
Part A: Change From Baseline in Modified CDQ-24 Score at Week 158
units on a scalePart A: SD-809
Part A: Change From Baseline in Modified CDQ-24 Score at Week 158-6.3 ± 2.61

Adverse events

Collected over Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A and Part B Participants8/337 (2.4%)68/337 (20.2%)172/337 (51%)
Part C: SD-8092/80 (2.5%)5/80 (6.3%)5/80 (6.3%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventPart A and Part B ParticipantsPart C: SD-809
SchizophreniaPsychiatric disorders5/3370/80
Cardiac failureCardiac disorders2/3371/80
PneumoniaInfections and infestations4/3371/80
DehydrationMetabolism and nutrition disorders1/3371/80
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/3371/80
Acute myocardial infarctionCardiac disorders0/3371/80
Schizophrenia, paranoid typePsychiatric disorders0/3371/80
Circulatory collapseVascular disorders0/3371/80
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/3370/80
Suicidal ideationPsychiatric disorders3/3370/80
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPart A and Part B ParticipantsPart C: SD-809
AnxietyPsychiatric disorders41/3370/80
DepressionPsychiatric disorders35/3370/80
SomnolenceNervous system disorders34/3370/80
Weight decreasedInvestigations32/3370/80
Urinary tract infectionInfections and infestations31/3370/80
DiarrhoeaGastrointestinal disorders27/3370/80
HeadacheNervous system disorders24/3370/80
HypertensionVascular disorders23/3371/80
DyskinesiaNervous system disorders22/3372/80
NasopharyngitisInfections and infestations20/3372/80

Baseline characteristics

ITT population included all participants who were enrolled in the study, regardless of whether or not a participant received a dose of study drug.

Age, Continuous
Age, Continuous(years)SD-809
Mean56.9 ± 10.65
Sex: Female, Male
Sex: Female, Male(Participants)SD-809
Female188
Male149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SD-809
Hispanic or Latino28
Not Hispanic or Latino300
Unknown or Not Reported9
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SD-809
Race — American Indian or Alaskan Native1
Race — Asian2
Race — Black69
Race — White264
Race — Other1
Total Motor Abnormal Involuntary Movement Scale (AIMS) Score
Total Motor Abnormal Involuntary Movement Scale (AIMS) Score(units on a scale)SD-809
Mean10.7 ± 4.68
AIMS Individual Items (8-10) Scores
AIMS Individual Items (8-10) Scores(units on a scale)SD-809
Severity of abnormal movements2.6 ± 0.78
Incapacitation due to abnormal movements2.0 ± 1.07
Participant's awareness of abnormal movements2.2 ± 1.08
Modified Craniocervical Dystonia Questionnaire 24 (CDQ-24) Score
Modified Craniocervical Dystonia Questionnaire 24 (CDQ-24) Score(units on a scale)SD-809
Mean29.2 ± 18.96
08

Study locations

82 sites
  • Teva Investigational Site 145
    Tuscaloosa, Alabama 35404, United States
  • Teva Investigational Site 107
    Anaheim, California 92804, United States
  • Teva Investigational Site 108
    Anaheim, California 92805, United States
  • Teva Investigational Site 123
    Glendale, California 91206, United States
  • Teva Investigational Site 160
    Irvine, California 92614, United States
  • Teva Investigational Site 176
    Loma Linda, California 92354, United States
  • Teva Investigational Site 121
    Los Angeles, California 90033, United States
  • Teva Investigational Site 147
    Los Angeles, California 90095-1769, United States
  • Teva Investigational Site 174
    Norwalk, California 90650, United States
  • Teva Investigational Site 130
    Oceanside, California 92056, United States
  • Teva Investigational Site 102
    Orange, California 92868, United States
  • Teva Investigational Site 104
    San Bernardino, California 92408, United States
  • Teva Investigational Site 110
    San Diego, California 92108, United States
  • Teva Investigational Site 169
    San Rafael, California 94901, United States
  • Teva Investigational Site 129
    Englewood, Colorado 80113, United States
  • Teva Investigational Site 139
    New Haven, Connecticut 06519, United States
  • Teva Investigational Site 156
    Washington, District of Columbia 20007, United States
  • Teva Investigational Site 157
    Boca Raton, Florida 33486, United States
  • Teva Investigational Site 117
    Gainesville, Florida 32607, United States
  • Teva Investigational Site 150
    Lake City, Florida 32025, United States
  • Teva Investigational Site 153
    Miami, Florida 33135, United States
  • Teva Investigational Site 162
    Miami, Florida 33165, United States
  • Teva Investigational Site 112
    Orlando, Florida 32803, United States
  • Teva Investigational Site 144
    Port Charlotte, Florida 33980, United States
  • Teva Investigational Site 155
    Augusta, Georgia 30912, United States
  • Teva Investigational Site 165
    Decatur, Georgia 30033, United States
  • Teva Investigational Site 131
    Chicago, Illinois 60611, United States
  • Teva Investigational Site 154
    Baltimore, Maryland 21287, United States
  • Teva Investigational Site 101
    Glen Burnie, Maryland 21061, United States
  • Teva Investigational Site 118
    Creve Coeur, Missouri 63141, United States
  • Teva Investigational Site 142
    Kansas City, Missouri 64108, United States
  • Teva Investigational Site 175
    Saint Louis, Missouri 63104, United States
  • Teva Investigational Site 161
    Saint Louis, Missouri 63109, United States
  • Teva Investigational Site 178
    Lincoln, Nebraska 68526-9467, United States
  • Teva Investigational Site 128
    Albuquerque, New Mexico 87106, United States
  • Teva Investigational Site 146
    Raleigh, North Carolina 27610, United States
  • Teva Investigational Site 114
    Garfield Heights, Ohio 44125, United States
  • Teva Investigational Site 133
    Charleston, South Carolina 29425, United States
  • Teva Investigational Site 149
    Memphis, Tennessee 38163, United States
  • Teva Investigational Site 151
    Fort Worth, Texas 76104, United States
  • Teva Investigational Site 115
    Salt Lake City, Utah 84105, United States
  • Teva Investigational Site 141
    Salt Lake City, Utah 84108, United States
  • Teva Investigational Site 167
    Richland, Washington 99352, United States
  • Teva Investigational Site 166
    Waukesha, Wisconsin 53188, United States
  • Teva Investigational Site 559
    Havirov, 736 01, Czechia
  • Teva Investigational Site 556
    Hostivice, 999999, Czechia
  • Teva Investigational Site 535
    Litomerice, 412 01, Czechia
  • Teva Investigational Site 557
    Plzen, 312 00, Czechia
  • Teva Investigational Site 533
    Prague 10, 100 00, Czechia
  • Teva Investigational Site 530
    Prague 6, 16000, Czechia
  • Teva Investigational Site 502
    Gera, 07551, Germany
  • Teva Investigational Site 504
    Mainz, 55131, Germany
  • Teva Investigational Site 540
    Balassagyarmat, 999999, Hungary
  • Teva Investigational Site 538
    Budapest, 1135, Hungary
  • Teva Investigational Site 541
    Budapest, 1148, Hungary
  • Teva Investigational Site 539
    Doba, 8482, Hungary
  • Teva Investigational Site 546
    Gyor, H-9024, Hungary
  • Teva Investigational Site 545
    Kalocsa, 6300, Hungary
  • Teva Investigational Site 514
    Belchatow, 97-400, Poland
  • Teva Investigational Site 554
    Bialystok, 15-756, Poland
  • Teva Investigational Site 510
    Bydgoszcz, 85-015, Poland
  • Teva Investigational Site 519
    Bydgoszcz, 85-080, Poland
  • Teva Investigational Site 536
    Bydgoszcz, 85-156, Poland
  • Teva Investigational Site 523
    Chelmno, 86-200, Poland
  • Teva Investigational Site 517
    Choroszcz, 16-070, Poland
  • Teva Investigational Site 513
    Gdansk, 80-952, Poland
  • Teva Investigational Site 512
    Katowice, 40-097, Poland
  • Teva Investigational Site 552
    Katowice, 40-123, Poland
  • Teva Investigational Site 520
    Krakow, 30-349, Poland
  • Teva Investigational Site 509
    Krakow, 31-505, Poland
  • Teva Investigational Site 508
    Lodz, 90-130, Poland
  • Teva Investigational Site 511
    Lublin, 20-064, Poland
  • Teva Investigational Site 524
    Lublin, 20-831, Poland
  • Teva Investigational Site 549
    Olsztyn, 10-443, Poland
  • Teva Investigational Site 522
    Torun, 87-100, Poland
  • Teva Investigational Site 550
    Warszawa, 00-465, Poland
  • Teva Investigational Site 516
    Wroclaw, 50-227, Poland
  • Teva Investigational Site 529
    Bratislava, 826 06, Slovakia
  • Teva Investigational Site 525
    Hronovce, 935 61, Slovakia
  • Teva Investigational Site 527
    Kosice, 04017, Slovakia
  • Teva Investigational Site 528
    Rimavska Sobota, 979 12, Slovakia
  • Teva Investigational Site 526
    Roznava, 04801, Slovakia
09

References and documents

Publications

  • Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1317-1323. doi: 10.1136/jnnp-2018-319918. Epub 2019 Jul 10. PubMed 31296586 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Dec 2019, 61 months.

Results were first posted in Mar 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2014
First posted
Jul 24, 2014
StartActual
Oct 20, 2014
Primary completionActual
Dec 6, 2019
CompletionActual
Dec 14, 2020
Results first posted
Mar 1, 2021
Last update
Apr 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02198794
Responsible party
Sponsor
First posted
Jul 24, 2014
Start date
Oct 20, 2014
Primary completion
Dec 6, 2019
Completion
Dec 14, 2020
Results posted
Mar 1, 2021
Last update
Apr 1, 2022

Study contacts

Teva Medical Expert, M.D.
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deutetrabenazine

Start the discussion